Our laboratory is interested in studying the intersection between lung cancer and immunology. We are currently focused on co-opting innate immune signaling pathways and tumor-associated T cell populations to target diverse subsets of lung cancer.

The Cardiovascular Pharmacotherapy Research Lab integrates molecular epidemiology, clinical pharmacology, clinical trials and population health science to identify new pathways and therapeutic strategies for the prevention of heart failure. Our team conducts cross-disciplinary, mechanism-focused clinical research to translate biologic discoveries into interventions with meaningful public health impact. 

The Zechner Lab applies molecular and cell biology techniques to investigate how mammalian cells regulate their phosphate homeostasis and sensing using the ubiquitous phosphate transporter PiT1/SLC20A1 as a model.

Ying Lab focuses on the development and clinical translation of soft medical devices, leveraging advanced design and fabrication techniques to tackle critical, unresolved challenges in human health. Current efforts in my lab center on hydrogel bioadhesives, soft medical robots, and ingestible bioelectronics aimed at enabling tissue-interfacing diagnostics and therapeutics in extreme body environments.

Dr. Mizuno's laboratory studies autonomic control of the cardiovascular system, particularly the underlying alterations in circulatory control in type 1 or type 2 diabetes and Alzheimer’s disease.

The Moe Lab specializes in translational pathophysiology that spans from individual molecules, in vitro cell models, in vivo animal models, to metabolic human studies. 

We are dedicated to uncovering how G protein–coupled receptors (GPCRs) regulate metabolism and contribute to health and disease. Our research aims to translate these discoveries into new insights and therapeutic strategies.

Using patient-specific stem cells, tissue engineering, and omics technologies to develop precision medicine for cardiovascular disease.

The Bann Laboratory focuses on discovering novel mechanistic targets to treat heart failure. We aim to identify regulators of cardiac cell fate reprogramming and regeneration as a molecular strategy to repair and heal the heart following injury.

The Singal & Rich research group focuses on generating critical insights to improve the entire spectrum of liver cancer care. Our studies involve assessing and promoting novel practices, imaging, and blood-based biomarkers to improve risk stratification, screening, early detection and outcomes for patients with hepatocellular carcinoma and other primary liver cancers.